SMAP2

Across TCGA pan-cancer cohorts, SMAP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMAP2 data layer compared with 20 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SMAP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMAP2 expression acts as an unfavorable survival marker.

OV, STAD, and SKCM are the cancer types where SMAP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.165	0.541	.004	18	view →
STAD	OS	Median	II,III,IV	0.222	0.710	.005	9	view →
SKCM	DFS	Median	III,IV	0.046	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMAP2–OV (DFS)

Open the OV breakdown →